NCT03566485View on ClinicalTrials.gov

Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 10, 2018

Primary Completion Date

December 10, 2020

Study Completion Date

December 10, 2020

Conditions
Stage III Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast CancerEstrogen Receptor-positiveHER2/Neu Negative
Interventions
DRUG

Atezolizumab

Given by IV

DRUG

Cobimetinib

Given by mouth

DRUG

Idasanutlin

Given by mouth

Trial Locations (1)

3720932

Vanderbilt-Ingram Cancer Center, Nashville

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Stand Up To Cancer

OTHER

lead

Vanderbilt-Ingram Cancer Center

OTHER